Eden Miller, DO, FOMA
Dr. Eden Miller is an Osteopathic Family Practitioner. She received her medical degree from AT Still University Kirksville College of Osteopathic Medicine (KCOM) in Kirksville, Missouri, in 1997. Dr. Miller then returned to the Northwest to complete her residency in Family Practice at East Moreland Hospital in Portland, Oregon. She recently completed her board certification in Obesity Management by the American Board of Obesity Medicine. Dr. Miller is the founder of Diabetes Nation, a nonprofit organization, and CEO of Diabetes and Obesity Care, where she practices in Bend, Oregon.
Dr. Miller has cultivated a special interest in diabetes after contracting type-1 diabetes while in medical school. Out of that personal experience, her practice has extended into a subspecialty in diabetes care. She is a passionate speaker and has given over 1000 lectures in the field of diabetes to health care providers and patients on subjects such as Diabetes Management, CGM Technology, Insulin Pump Therapy, Obesity, and Metabolism intervention, Clinical Research, and Healthcare Policy. Her adage for care is "she only succeeds as a provider if she turns patients into experts on their own disease."
Dr. Miller believes that a physiologic patient individualized approach to diabetes intervention is crucial to success. She feels if our nation is to triumph over the ravages of diabetes, a collaborative effort; unhindered by fear of personal scrutiny, and barriers for effective treatment need to be removed. For her, diabetes and obesity care provide the foundational model to impact the people that represent this disease and begin the process of restoring hope back into their lives.
Dr. Miller discloses that she is on the advisory board for Abbott, Eli Lilly USA, Boehringer Ingelheim, Sanofi Aventis, Novo Nordisk, Merck, Bayer, Diabetes Wise-Stanford University, MicroGenDX, Plenity, and the American Diabetes Association. In addition, she discloses she is a promotional speaker for Abbott, Eli Lilly USA, Boehringer Ingelheim, and Novo Nordisk. She also discloses she does research for Pendulum and Abbott. All relevant financial relationships have been mitigated.
